IP Library Granted Patent US 7,998,462
Granted Patent B2
US 7,998,462 · App. 11/872,984 · Granted Aug 16, 2011

Linkers for anchoring targeting ligands

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,998,462
App. No.
11/872,984
Granted
Aug 16, 2011
Kind
B2
Abstract

An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo.

Claims (21)

1. A compound of the formula

targeting agent-SO 2 -phenylene-O(CH 2 ) n CONH(CH 2 ) n NHCO(CH 2 ) n —CONH(CH 2 ) n O(CH 2 CH 2 O) x CH 2 CH 2 OCZ-anchor  (1)

wherein each n is independently 1-4;

x is an integer of 20-60;

Z is ═NH or ═O;

the targeting agent is a moiety containing an amino group or a hydroxyl group for coupling to the remainder of the molecule; and

the anchor is a lipophilic compound for embedding the compound in a lipid based particulate.

2. The compound of claim 1 wherein the targeting agent targets an integrin.

3. The compound of claim 1 wherein the targeting agent is an antibody or immuno-reactive fragment thereof, or

wherein the targeting agent is a ligand for a receptor.

4. The compound of claim 1 wherein the anchor is the residue of a phosphatidyl lipid.

5. The compound of claim 4 wherein the anchor is a residue of phosphatidyl ethanolamine.

6. The compound of claim 1 wherein x is an integer of 40-50.

7. A lipid-based particulate formulation wherein said lipid-based particles comprise a multiplicity of molecules of the compound of claim 1 .

8. The formulation of claim 7 wherein the particles further comprise a therapeutic or diagnostic agent.

9. The particulate formation of claim 8 wherein the therapeutic agent is a drug, and/or

wherein the diagnostic agent is a chelated metal for MRI imaging, or

wherein the therapeutic or diagnostic agent is a radionuclide.

10. The particulate formation of claim 8 wherein the lipid-based particles are liposomes, micelles, or nanoparticles containing cores consisting of liquid fluorocarbon coated with lipid/surfactant.

11. The particulate formation of claim 10 wherein the lipid-based particles are nanoparticles containing cores consisting of liquid fluorocarbon coated with lipid/surfactant.

12. A method to target a desired destination in a subject which comprises administering to said subject the formulation of claim 8 .

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 3, 2010
From: PROLOG CAPITAL II, L.P.; CHARTER LIFE SCIENCES, L.P.; MEMPHIS BIOMED VENTURES II, L.P.; TRIATHLON MEDICAL VENTURES FUND, L.P.; ADVANTAGE CAPITAL COMMUNITY DEVELOPMENT FUND XV, LLC; ALAFI CAPITAL COMPANY, LLC; APJOHN VENTURES FUND, LP; VECTIS LIFE SCIENCES FUND I, L.P.; WICKLINE, SAMUEL A., M.D.; 1998 CO-INVESTING LLC; C. AGANOSTOPOULOS REVOCABLE TRUST U/A 12/21/1978
To: KEREOS, INC.
Reel/Frame 024320/0741 →
SECURITY AGREEMENT Recorded Jul 17, 2009
From: KEREOS, INC.
To: PROLOG CAPITAL II, L.P.; CHARTER LIFE SCIENCES, L.P.; MEMPHIS BIOMED VENTURES II, L.P.; TRIATHLON MEDICAL VENTURES FUND L.P.; ADVANTAGE CAPITAL COMMUNITY DEVELOPMENT FUND XV, LLC; ALAFI CAPITAL COMPANY, LLC; APJOHN VENTURES FUND, LP; VECTIS LIFE SCIENCES FUND I, L.P.; WICKLINE, SAMUEL A., M.D.; 1998 CO-INVESTING LLC; C. AGANOSTOPOULOS REVOCABLE TRUST U/A 12/21/1978
Reel/Frame 022960/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2008
From: MCGHEE, WILLIAM D.
To: KEREOS, INC.
Reel/Frame 021425/0598 →